Adjuvant Anti–PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese Patients
JCO Global Oncology · 2025
DOI: 10.1200/go-24-00644 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Shigeru Koizumi und 49 weiteren Autor:innen. Beteiligte Einrichtung: Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Adjuvant anti–PD-1 (adj PD-1) antibodies are extensively used to improve survival in patients with resected melanoma. Clinical trials on adj PD-1 antibodies have revealed significant improvements in recurrence-free survival (RFS); however, few of these trials have included patients with acral melanoma (AM). METHODS Clinical data were retrospectively collected from Japanese patients who underwent resection of stage III sole AM between 2014 and 2021. Survival outcomes, including RFS, distant metastasis-free survival (DMFS), and overall survival (OS), were compared between patients without adjuvant therapy (OBS group) and those receiving adj PD-1 group. RESULTS This study included 139 patients (OBS: 79; adj PD-1: 60), with a median follow-up of 2.6 years. The baseline characteristics were comparable, except for age and nodal metastasis. No significant differences in survival were observed between the OBS and adj PD-1 groups (3-year RFS: 36.7% v 27.5%, P = .13; 3-year DMFS: 51.0% v 45.3%, P = .51; 3-year OS: 65.3% v 67.4%, P = .45). Multivariate analysis showed no survival benefit of adj PD-1 (RFS: hazard ratio [HR], 1.25, P = .29; DMFS: HR, 1.03, P = .89; and OS: HR, 0.69, P = .23). Each survival outcome after propensity score matching confirmed no significant difference between the matched OBS group (n = 52) and adj PD-1 group (n = 52; 3-year RFS: 34.3% v 25.9%, P = .22; 3-year DMFS: 45.6% v 46.5%, P = .85; 3-year OS: 60.7% v 68.9%, P = .29). CONCLUSION Adj PD-1 did not improve the prognosis in sole AM. However, further studies are essential to evaluate the efficacy of the adj anti–PD-1 antibody in AM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan.
- Department of Dermatology, Chiba University, Chiba, Japan.
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Dermatology, Mie University, Mie, Japan.
- Department of Dermatology, Shinshu University, Matsumoto, Japan.
ORCID-Profile: Shigeru Koizumi, Naoya Yamazaki, Yukiko Kiniwa, Sayuri Sato, Masahito Yasuda, Yutaka Kuwatsuka, Takeo Maekawa, Takuya Miyagawa, Shigeto Matsushita, Takeru Funakoshi, Hiraku Kokubu, Yuki Yamamoto, Kazuhiro Inafuku, Toshihiko Hoashi, Nobuo Kanazawa, Utsugi Iwasawa, Takafumi Kadono, Naohito Hatta, Eiji Nakano, Dai Ogata, Satoshi Fukushima, Kenta Nakama, Yasuhiro Nakamura
Zitieren
APA
Koizumi, S., Yamazaki, N., Ichigozaki, Y., Kitagawa, H., Kiniwa, Y., Sato, S., Takai, T., Doi, R., Ito, T., Yasuda, M., Kuwatsuka, Y., Maekawa, T., Asai, J., Miyagawa, T., Matsushita, S., Funakoshi, T., Yamamoto, Y., Inozume, T., Kishi, A., …, & Nakamura, Y. (2025). Adjuvant Anti–PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese Patients. JCO Global Oncology. https://doi.org/10.1200/go-24-00644
Vancouver
Koizumi S, Yamazaki N, Ichigozaki Y, Kitagawa H, Kiniwa Y, Sato S, et al. Adjuvant Anti–PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese Patients. JCO Global Oncology. 2025. doi:10.1200/go-24-00644
BibTeX
@article{Koizumi2025,
author = {Koizumi, Shigeru and Yamazaki, Naoya and Ichigozaki, Yuki and Kitagawa, Hiroshi and Kiniwa, Yukiko and Sato, Sayuri and Takai, Toshihiro and Doi, Reiichi and Ito, Takamichi and Yasuda, Masahito and Kuwatsuka, Yutaka and Maekawa, Takeo and Asai, Jun and Miyagawa, Takuya and Matsushita, Shigeto and Funakoshi, Takeru and Yamamoto, Yosuke and Inozume, Takashi and Kishi, Akiko and Takenouchi, Tatsuya and Kokubu, Hiraku and Ito, Shusaku and Umeda, Yoshiyasu and Yamamoto, Yuki and Ishizuki, Shoichiro and Iino, Shiro and Uchi, Hiroshi and Nakagawa, Tomoe and Inafuku, Kazuhiro and Haga, Takahiro and Kaneko, Takahide and Nakagawa, Masahiro and Kamiya, Hideki and Arima, Masaru and Hoashi, Toshihiko and Hiura, Azusa and Kanazawa, Nobuo and Manabe, Keiko and Ishikawa, Masashi and Asagoe, Kenji and Iwasawa, Utsugi and Kadono, Takafumi and Hatta, Naohito and Minami, Shoichiro and Nakano, Eiji and Ogata, Dai and Fukushima, Satoshi and Uhara, Hisashi and Nakama, Kenta and Nakamura, Yasuhiro},
title = {Adjuvant Anti–PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese Patients},
journal = {JCO Global Oncology},
year = {2025},
doi = {10.1200/go-24-00644}
}
EUVIMED